CRITICALGLP-1 / Weight LossFDA Warning Letter · September 9, 2025

Lumimeds

Atlas ID: 2025-09-fda-lumimeds-mo7v6u

FDA issued a warning letter to Lumimeds (Las Vegas, NV) in September 2025 after reviewing their website and finding that marketing claims for compounded semaglutide and tirzepatide falsely implied equivalence with FDA-approved brand-name GLP-1 medications. Specifically, Lumimeds claimed these compounded products contain 'the same active ingredient as the brand name medications' and that 'GLP-1 was FDA-approved in 2017,' misleading consumers into believing the compounded products share FDA-approved status. FDA determined these claims constitute misbranding under FDCA sections 502(a) and 502(bb), and directed Lumimeds to immediately cease the offending language and respond within 15 working days, warning that failure to comply could result in seizure or injunction.

Flagged claims (2)

GLP-1 Injections contain GLP-1, which mimics a naturally occurring hormone in the body. This is the same active ingredient used in brand name GLP-1 weight-loss medications. GLP-1 was FDA-approved in 2017 . . . . It was FDA-approved in 2021 for weight loss.

FDA trademark misuse · fda-approved-misuse-compounded-drug

Doctors frequently recommend Compounded Tirzepatide or Compounded Semaglutide, both of which are GLP-1 agonists with the same active ingredient as the brand name medications.

FDA trademark misuse · compounded-equivalence-implied

Required actions (3)

You should take immediate action to address any violations (including, for example, ceasing and desisting from using the language cited above that misbrands the product).

Claim removal

Within fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)'s Office of Compliance describing the specific steps you have taken to address any violations.

Response required · 15 days

Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.

Injunction

Source

www.fda.gov · FDA Warning Letter

Does your site contain similar claims?

The free site audit scans your whole site against every entry in this Atlas. Most glp-1 / weight loss sites match 3-6 patterns.

Run my free site audit

Worried about one specific page, ad, or email? Paste it into the free Claim Checker and see what the FDA and FTC would flag, with the precedent next to each one. No email required.

Check specific copy in the Claim Checker